Physician profile
Ban Wang
NPI 1073002689
$1,496.50
in general payments reported to CMS, 2019-2025
12 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $645 · 2024: $529 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382 · Education: $99.95 · Consulting Fee: $14.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.60 |
| Education | $99.95 |
| Consulting Fee | $14.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $375.63 | 2023-2024 | Nucala |
| Astrazeneca Pharmaceuticals LP | $298.82 | 2023 | Fasenra |
| Genentech USA, INC. | $147.30 | 2024 | Xolair |
| Blueprint Medicines Corporation | $138.96 | 2024 | Ayvakit |
| Genzyme Corporation | $121.38 | 2025 | |
| Pharming Healthcare, INC. | $120.57 | 2024-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $115.17 | 2023-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Grifols USA, LLC | $32.93 | 2024-2025 | Xembify |
| Kaleo, INC. | $17.00 | 2024 | Auvi-Q |
| Adma Biomanufacturing LLC | $14.95 | 2025 | |
| Insulet Corporation | $13.84 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ban Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.